Showing results (11-20 of 32) with videos related to
Sort By:
Pageof 4
Arteriosclerosis, Thrombosis, and Vascular Biology|February 18, 2003
Short-term triglyceride lowering with fenofibrate improves vasodilator function in subjects with hypertriglyceridemiaWarren H Capell, Christopher A DeSouza, Paul Poirier, et al.The American Journal of Clinical Nutrition|January 29, 2010
Lack of suppression of circulating free fatty acids and hypercholesterolemia during weight loss on a high-fat, low-carbohydrate dietTeri L Hernandez, Julie P Sutherland, Pamela Wolfe, et al.American Heart Journal|January 5, 2022
Rationale and design of a study to assess the safety and efficacy of rNAPc2 in COVID-19: the Phase 2b ASPEN-COVID-19 trialConnie N Hess, Warren H Capell, Michael R Bristow, et al.American Heart Journal|February 12, 2021
Rationale and design for the study of rivaroxaban to reduce thrombotic events, hospitalization and death in outpatients with COVID-19: The PREVENT-HD studyWarren H Capell, Elliot S Barnathan, Gregory Piazza, et al.Circulation|June 21, 2017
A Structured Review of Antithrombotic Therapy in Peripheral Artery Disease With a Focus on Revascularization: A TASC (InterSociety Consensus for the Management of Peripheral Artery Disease) InitiativeConnie N Hess, Lars Norgren, Gary M Ansel, et al.Kidney360|May 4, 2026
Thyroid Function with Continuous KRT: A Prospective StudyMatthew Kennis, David Madison, North Foulon, et al.American Heart Journal|May 15, 2018
Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD)Warren H Capell, Marc P Bonaca, Mark R Nehler, et al.Journal of the American College of Cardiology|August 21, 2024
Low-Dose Rivaroxaban Plus Aspirin in Fragile Patients After Lower Extremity RevascularizationMario Enrico Canonico, Cecilia C Low Wang, Judith Hsia, et al.JACC. Advances|May 13, 2025
Preserving Trial Endpoint Specificity and Cause of Death Attribution in Cardiovascular Trials: Insights From MARINERShea E Hogan, Mario Enrico Canonico, Robert W King, et al.Journal of the American College of Cardiology|May 19, 2021
Total Ischemic Event Reduction With Rivaroxaban After Peripheral Arterial Revascularization in the VOYAGER PAD TrialRupert M Bauersachs, Michael Szarek, Marianne Brodmann, et al.Pageof 4